Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Inclusion Criteria

• •Patients with severe combined immunodeficiency syndrome:
• •* SCID with presence of B lymphocytes
• •* X-linked SCID (presence of B lymphocytes)
• •* Autosomal recessive SCID
• •Patients with severe combined immunodeficiency syndrome:
• •* SCID with absence of T and B lymphocytes
• •Patients with severe combined immunodeficiency syndrome:
• •* Purine metabolite deficiencies, deficiencies of the purine metabolites
• •* Adenosine deaminase (ADA) deficiency
• •* Purine nucleoside phosphorylase (PNP) deficiency
• •DONOR: Related donor who is human leukocyte antigen (HLA) genotypically identical at least at one haplotype and may be genotypically or phenotypically identical for serological typing for HLA-A, B, C, and at the allele level for DRB1 and DQB1; related donors other than siblings must be matched at HLA-A, B, and C (at highest resolution available at the time of donor selection) and at DRB1 and DQB1 by deoxyribonucleic acid (DNA) typing; if more than one HLA-identical sibling is available, priority will be given to the oldest normal donor
• •DONOR: Unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1 by DNA typing at the highest resolution routinely available at the time of donor selection; only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing